×
Matthew Lepoire public
[search 0]
×
Best Matthew Lepoire podcasts we could find (updated December 2019)
Best Matthew Lepoire podcasts we could find
Updated December 2019
Join millions of Player FM users today to get news and insights whenever you like, even when you're offline. Podcast smarter with the free podcast app that refuses to compromise. Let's play!
Join the world's best podcast app to manage your favorite shows online and play them offline on our Android and iOS apps. It's free and easy!
More
show episodes
 
B
Breaking Biotech
Monthly+
 
Matt breaks down relevant biotech stocks, analyzing their data and determining if they are a good investment.
 
B
Breaking Biotech
Monthly+
 
Matt breaks down relevant biotech stocks, analyzing their data and determining if they are a good investment.
 
Loading …
show series
 
Happy Thanksgiving! In this video, I talk about all things related to eye diseases caused by over-proliferating endothelial cells. These diseases are currently treated by monthly intravitreal injections but there are new therapies in clinical trials that are likely to unseat them. I touch on #RGNX, #ADVM and #KOD as well as some others that hav ...…
 
Happy Thanksgiving! In this video, I talk about all things related to eye diseases caused by over-proliferating endothelial cells. These diseases are currently treated by monthly intravitreal injections but there are new therapies in clinical trials that are likely to unseat them. I touch on #RGNX, #ADVM and #KOD as well as some others that hav ...…
 
I'm back! Here are the companies I touch on in this episode (recorded on Nov 14, 2019): Sarepta: 2:30Trevena: 4:08Viking: 5:40Regenxbio: 7:47Biogen: 12:35Amarin: 17:38 all of this is only opinion and nothing I have said should be taken as investment advice www.breakingbiotech.com Support Breaking Biotech by donating to their Tip Jar: https://ti ...…
 
I'm back! Here are the companies I touch on in this episode (recorded on Nov 14, 2019): Sarepta: 2:30Trevena: 4:08Viking: 5:40Regenxbio: 7:47Biogen: 12:35Amarin: 17:38 all of this is only opinion and nothing I have said should be taken as investment advice www.breakingbiotech.com Support Breaking Biotech by donating to their Tip Jar: https://ti ...…
 
Hey everybody, we made it to #50! In this episode, I chat with Nathan Weinstein from Aegis Capital about Acasti Pharma. We discuss the omega-3 space and Acasti's EPA/DHA formulation called CaPre. Acasti is seeking the approval of CaPre for the indication of severe hypertriglyceridemia and has two pivotal catalysts at the end of the year, which ...…
 
Hey everybody, we made it to #50! In this episode, I chat with Nathan Weinstein from Aegis Capital about Acasti Pharma. We discuss the omega-3 space and Acasti's EPA/DHA formulation called CaPre. Acasti is seeking the approval of CaPre for the indication of severe hypertriglyceridemia and has two pivotal catalysts at the end of the year, which ...…
 
Today, I talk breast cancer and how Odonate's oral Taxane (Tesataxel) could garner the attention of doctor's looking to alleviate the burden of IV chemotherapy infusion in their patients. I discuss the latest macro news, biotech news, and compare previous Taxane revenue to see if my model is reasonable. www.breakingbiotech.com biotech #breaking ...…
 
Today, I talk breast cancer and how Odonate's oral Taxane (Tesataxel) could garner the attention of doctor's looking to alleviate the burden of IV chemotherapy infusion in their patients. I discuss the latest macro news, biotech news, and compare previous Taxane revenue to see if my model is reasonable. www.breakingbiotech.com biotech #breaking ...…
 
In this video, I discuss the details of the advisory committee that recently occurred regarding Aimmune Therapeutics' peanut allergy treatment, Palforzia (formerly AR101). The committee voted in support of approval and should pave the way for a positive PDUFA decision. this is not investment advice www.breakingbiotech.com Support Breaking Biote ...…
 
In this video, I discuss the details of the advisory committee that recently occurred regarding Aimmune Therapeutics' peanut allergy treatment, Palforzia (formerly AR101). The committee voted in support of approval and should pave the way for a positive PDUFA decision. this is not investment advice www.breakingbiotech.com Support Breaking Biote ...…
 
In this video, I talk about Sarepta and their issues regarding the CRL received for Golodirsen. I also take a close look at Iovance Biotherapeutics and their tumor infiltrating lymphocyte cell therapy for cancer treatment. this is not investment advice breakingbiotech #SRPT #IOVA www.breakingbiotech.com Support Breaking Biotech by donating to t ...…
 
In this video, I talk about Sarepta and their issues regarding the CRL received for Golodirsen. I also take a close look at Iovance Biotherapeutics and their tumor infiltrating lymphocyte cell therapy for cancer treatment. this is not investment advice breakingbiotech #SRPT #IOVA www.breakingbiotech.com Support Breaking Biotech by donating to t ...…
 
Hey everyone! In this video, I discuss the relationship history between Amarin and the FDA regarding their EPA medication (Vascepa) for the lowering of triglycerides. I believe the difficulty #AMRN has had with the FDA in the past has made the market concerned about Vascepa's future given recent announcement of an advisory committee meeting for ...…
 
Hey everyone! In this video, I discuss the relationship history between Amarin and the FDA regarding their EPA medication (Vascepa) for the lowering of triglycerides. I believe the difficulty #AMRN has had with the FDA in the past has made the market concerned about Vascepa's future given recent announcement of an advisory committee meeting for ...…
 
Hey everybody, today I talk about the upcoming advisory committee meeting, which will lead to a recommendation (or not) for the approval of Descovy for pre-exposure prophylaxis (PrEP) in high-risk individuals. I also go through the latest ICER reports on AIMT and AMRN. I mention a short-term trade idea but remember to do your own due diligence ...…
 
Hey everybody, today I talk about the upcoming advisory committee meeting, which will lead to a recommendation (or not) for the approval of Descovy for pre-exposure prophylaxis (PrEP) in high-risk individuals. I also go through the latest ICER reports on AIMT and AMRN. I mention a short-term trade idea but remember to do your own due diligence ...…
 
Hi all, today I talk about the #MRKR interim update of their MultiTAA treatment in pancreatic cancer. I go through the data in all 3 arms and analyze whether or not they see an actual effect of their unique therapy. www.breakingbiotech.com this is not investment advice breaking biotech #biotech Support Breaking Biotech by donating to the tip ja ...…
 
Hi all, today I talk about the #MRKR interim update of their MultiTAA treatment in pancreatic cancer. I go through the data in all 3 arms and analyze whether or not they see an actual effect of their unique therapy. www.breakingbiotech.com this is not investment advice breaking biotech #biotech Support Breaking Biotech by donating to the tip ja ...…
 
Hey everybody, hope you're all doing well! In this video, I talk about Pfizer's DMD gene therapy update that indicates continued Sarepta hegemony in the space. I also talk about ContraVir and their NASH drug, CRV431. I must have drank too much coffee before recording because I made more than a couple errors this time around. So, if you're an au ...…
 
Hey everybody, hope you're all doing well! In this video, I talk about Pfizer's DMD gene therapy update that indicates continued Sarepta hegemony in the space. I also talk about ContraVir and their NASH drug, CRV431. I must have drank too much coffee before recording because I made more than a couple errors this time around. So, if you're an au ...…
 
Today, I cover the latest in biotech with a highlight on Immunomedics and their antibody-drug conjugates for breast cancer. this is not investment advicewww.breakingbiotech.com@matthewlepoire Support Breaking Biotech by donating to the tip jar: https://tips.pinecast.com/jar/breaking-biotechBy Matthew Lepoire
 
Today, I cover the latest in biotech with a highlight on Immunomedics and their antibody-drug conjugates for breast cancer. this is not investment advicewww.breakingbiotech.com@matthewlepoire Support Breaking Biotech by donating to the tip jar: https://tips.pinecast.com/jar/breaking-biotechBy Matthew Lepoire
 
Today, I talk about REGENXBIO and their in-house gene therapy candidates. Their most important asset in early clinical trials is RGX-314, indicated for wet AMD (and hopefuily Diabetic Retinopathy). This gene therapy could replace blockbuster drugs that treat millions patients, but is it a buy today? Follow me @matthewlepoirewww.breakingbiotech. ...…
 
Today, I talk about REGENXBIO and their in-house gene therapy candidates. Their most important asset in early clinical trials is RGX-314, indicated for wet AMD (and hopefuily Diabetic Retinopathy). This gene therapy could replace blockbuster drugs that treat millions patients, but is it a buy today? Follow me @matthewlepoirewww.breakingbiotech. ...…
 
Hi all, I'm back today talking about the approval of Avexis/Novartis' gene therapy for spinal muscular atrophy, Zolgensma. I also talk about how I came to a conclusion about whether or not I should short Biogen. Correction: The upcoming BIIB098 readout is not a pivotal study but a head-to-head against Tecfidera. Also, the partnership company is ...…
 
Hi all, I'm back today talking about the approval of Avexis/Novartis' gene therapy for spinal muscular atrophy, Zolgensma. I also talk about how I came to a conclusion about whether or not I should short Biogen. Correction: The upcoming BIIB098 readout is not a pivotal study but a head-to-head against Tecfidera. Also, the partnership company is ...…
 
Hi everybody, in this episode I take a deeper dive into pancreatic cancer and how Marker Therapeutics' MultiTAA T Cell therapy might fare against it. Thanks for listening! Follow me on twitter @matthewlepoire Support Breaking Biotech by donating to the tip jar: https://tips.pinecast.com/jar/breaking-biotech…
 
Hi everybody, in this episode I take a deeper dive into pancreatic cancer and how Marker Therapeutics' MultiTAA T Cell therapy might fare against it. Thanks for listening! Follow me on twitter @matthewlepoire Support Breaking Biotech by donating to the tip jar: https://tips.pinecast.com/jar/breaking-biotech…
 
Hey all, tonight I talk about the latest downswing in biotech/pharma and I breakdown Marker Therapeutics. This company has a novel platform to activate T cells for cancer treatment that significantly reduces side effects, which are common in CAR-T. I jumbled over explaining target optimization. Basically, the company is using the same antigen t ...…
 
Hey all, tonight I talk about the latest downswing in biotech/pharma and I breakdown Marker Therapeutics. This company has a novel platform to activate T cells for cancer treatment that significantly reduces side effects, which are common in CAR-T. I jumbled over explaining target optimization. Basically, the company is using the same antigen t ...…
 
In this video, I go through Sangamo's updated data with their Hemophilia A and Beta-Thalassemia treatments. I also talk about Viking Therapeutics' VK5211, a potent selective androgen receptor modulator. Follow me @matthewlepoire This is not investment advice www.breakingbiotech.com breakingbiotech #SGMO #VKTX…
 
In this video, I go through Sangamo's updated data with their Hemophilia A and Beta-Thalassemia treatments. I also talk about Viking Therapeutics' VK5211, a potent selective androgen receptor modulator. Follow me @matthewlepoire This is not investment advice www.breakingbiotech.com breakingbiotech #SGMO #VKTX…
 
Happy Sunday everyone! Today, I talk about: -#BIIB/Eisai and their decision to continue trials with compounds that reduce brain amyloid beta-ESSENCE interim data from #SRPT-The #VKTX abstract release and upgrade -More good news about #AMRN This is not investment advice, so do your own due diligence! www.breakingbiotech.com breakingbiotech #biotech…
 
Happy Sunday everyone! Today, I talk about: -#BIIB/Eisai and their decision to continue trials with compounds that reduce brain amyloid beta-ESSENCE interim data from #SRPT-The #VKTX abstract release and upgrade -More good news about #AMRN This is not investment advice, so do your own due diligence! www.breakingbiotech.com breakingbiotech #biotech…
 
Today I go through a trading idea for Trevena as well as the updated Amarin data. This is not investment advice. www.breakingbiotech.comBy Matthew Lepoire
 
Today I go through a trading idea for Trevena as well as the updated Amarin data. This is not investment advice. www.breakingbiotech.comBy Matthew Lepoire
 
In this episode, I talk about the latest news in the biotech sector with details on my DCF model for Amarin and their fish oil pill, vascepa. I also talk about the limb-girdle data from Sarepta. Hit the subscribe button! this is not investment advice www.breakingbiotech.comBy Matthew Lepoire
 
In this episode, I talk about the latest news in the biotech sector with details on my DCF model for Amarin and their fish oil pill, vascepa. I also talk about the limb-girdle data from Sarepta. Hit the subscribe button! this is not investment advice www.breakingbiotech.comBy Matthew Lepoire
 
In today's episode, I breakdown the ICPT NASH results, followed up by a quick take on SAGE and the latest buyout rumors. this is not investment advice Relevant links:http://ir.interceptpharma.com/news-releases/news-release-details/intercept-announces-positive-topline-results-pivotal-phase-3https://www.sagerx.com/ www.breakingbiotech.com…
 
In today's episode, I breakdown the ICPT NASH results, followed up by a quick take on SAGE and the latest buyout rumors. this is not investment advice Relevant links:http://ir.interceptpharma.com/news-releases/news-release-details/intercept-announces-positive-topline-results-pivotal-phase-3https://www.sagerx.com/ www.breakingbiotech.com…
 
On this episode, I talk about results from the Gilead Phase 3 NASH trial that announced no improvement in patients treated with Selonsertib (ASK1 inhibitor). I also talk about the DBVT BLA resubmission and a hot hot Q319 trading idea on CBIO. this is not investment advice, only my opinion and ideas www.breakingbiotech.comhttps://youtu.be/uGLXrB ...…
 
On this episode, I talk about results from the Gilead Phase 3 NASH trial that announced no improvement in patients treated with Selonsertib (ASK1 inhibitor). I also talk about the DBVT BLA resubmission and a hot hot Q319 trading idea on CBIO. this is not investment advice, only my opinion and ideas www.breakingbiotech.comhttps://youtu.be/uGLXrB ...…
 
Today, I talk about Sangamo's updated data from their talks at the WORLDSymposium. We saw updates on their MPSI and MPSII programs that the market responded to with big selling. I refer to their pre-clinical data and see how it compares to the updated human data. I finish up giving my predictions, which includes selling my 15 shares. Relevant l ...…
 
Today, I talk about Sangamo's updated data from their talks at the WORLDSymposium. We saw updates on their MPSI and MPSII programs that the market responded to with big selling. I refer to their pre-clinical data and see how it compares to the updated human data. I finish up giving my predictions, which includes selling my 15 shares. Relevant l ...…
 
Hey everybody! I'm back with a new video talking about news in January from my favorite biotech companies. There was a lot of interesting things from the JP Morgan Healthcare conference and there is a lot of anticipation for data coming out in Q1-2019. Here, I blast through some updates on $BMY $ESPR $SGMO $AMRN $SRPT $BIIB. Enjoy! https://yout ...…
 
Hey everybody! I'm back with a new video talking about news in January from my favorite biotech companies. There was a lot of interesting things from the JP Morgan Healthcare conference and there is a lot of anticipation for data coming out in Q1-2019. Here, I blast through some updates on $BMY $ESPR $SGMO $AMRN $SRPT $BIIB. Enjoy! https://yout ...…
 
Hey everybody, I hope you've all been enjoying the holidays. I talk about 3 things in this video: The federal reserve and chairman Powell's comments on their guidance and the economy. DBVT pulling their BLA and my opinion on both them and AIMT. CRISPR/Cas9 and the companies commercializing the tech. This is only my opinion and should not be con ...…
 
Hey everybody, I hope you've all been enjoying the holidays. I talk about 3 things in this video: The federal reserve and chairman Powell's comments on their guidance and the economy. DBVT pulling their BLA and my opinion on both them and AIMT. CRISPR/Cas9 and the companies commercializing the tech. This is only my opinion and should not be con ...…
 
Lots has happened since my last video! Today I talk about the updates from ASH 2018, with a focus on $BLUE and $GBT. I also talk about FATE, $MRNA, and the companies making bispecifics. This is not investment advice, but for information only. www.breakingbiotech.comBy Matthew Lepoire
 
Lots has happened since my last video! Today I talk about the updates from ASH 2018, with a focus on $BLUE and $GBT. I also talk about FATE, $MRNA, and the companies making bispecifics. This is not investment advice, but for information only. www.breakingbiotech.comBy Matthew Lepoire
 
Google login Twitter login Classic login